(Q40271712)

19 September 2017

Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? (English)

1 reference

19 September 2017

1

Odds FC

1 reference

19 September 2017

1 March 1998

1 reference

19 September 2017

Drug Resistance Updates

1 reference

19 September 2017

1

1 reference

19 September 2017

1

1 reference

19 September 2017

11-15

1 reference

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Predictive value of susceptibility tests for the outcome of antibacterial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Pseudomonas bacteremia. Review of 108 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Worldwide clinical experience with cefoperazone

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Analysis of 1,186 Episodes of Gram-Negative Bacteremia in Non-University Hospitals: The Effects of Antimicrobial Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

The in vitro synergistic inhibitory effect of human amniotic fluid and gentamicin on growth of Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Plasma and tissue concentrations of fluconazole and their correlation to breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2898%2980209-4

7 January 2021

10.1016/S1368-7646(98)80209-4

Identifiers

DOI

1 reference

19 September 2017

1 reference

PubMed ID

17092791